Clinical study of CB06-036 in chronic hepatitis B patients
Latest Information Update: 07 Apr 2022
At a glance
- Drugs CB06-036 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
Most Recent Events
- 07 Apr 2022 New trial record
- 31 Mar 2022 According to a Zhimeng Biopharma media release, the company plans to submit a clinical trial application to the National Medical Products Administration (NMPA) following the U.S. Phase I clinical trial to fast-track this study.